<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944563</url>
  </required_header>
  <id_info>
    <org_study_id>2021-SR-164</org_study_id>
    <nct_id>NCT04944563</nct_id>
  </id_info>
  <brief_title>Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field</brief_title>
  <official_title>Comparison of Segmentectomy Versus Lobectomy for Early-stage Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field: A Prospective and Multi-center RCT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether segmentectomy had non-inferiority long-term&#xD;
      oncological effects (disease-free survival and overall survival) compared with lobectomy in&#xD;
      the treatment of patients with early-stage non-small cell lung cancer ≤ 2 cm in the middle&#xD;
      third of lung field.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays, the role of segment resection in the treatment of non-small cell lung cancer ≤ 2 cm&#xD;
      in the outer third of the lung field has been evaluated in multiple studies. Recently,&#xD;
      professor Hisao Asamura released the long-term results of the JCOG0802 project in AATS 2021.&#xD;
      Segmentectomy had a higher 5-year overall survival (94.3% vs. 91.1%) than lobectomy (P &lt;&#xD;
      0.001) for non-small cell lung cancer ≤ 2 cm (CTR &gt; 0.5) in the outer third of the lung&#xD;
      field. However, a substantial portion of lung nodules was not located in the outer third, but&#xD;
      the middle third of the lung field. Whether segmentectomy has non-inferiority long-term&#xD;
      oncological effects compared to lobectomy for early-stage non-small cell lung cancer ≤ 2 cm&#xD;
      in the middle third of lung field remains unclear. This randomized controlled trial study&#xD;
      aims to investigate whether segmentectomy has non-inferiority long-term oncological effects&#xD;
      compared to lobectomy for early-stage non-small cell lung cancer ≤ 2 cm in the middle third&#xD;
      of the lung field.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year Disease-Free Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 60 months</time_frame>
    <description>The time interval from randomization to the earliest onset of any of the following events: tumor local recurrence, distant metastasis, and mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day Morbidity and mortality rates</measure>
    <time_frame>From date of the recruitment, assessed up to 30 days</time_frame>
    <description>The rates of complications and death related to treatment during perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function in the first year after surgery</measure>
    <time_frame>From date of the 3rd, 6th, and 12th month after surgery</time_frame>
    <description>The Forced expiratory volume in one second (FEV1) in liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year Disease-Free-Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 36 months</time_frame>
    <description>The time interval from randomization to the earliest onset of any of the following events: tumor local recurrence, distant metastasis, and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 60 months</time_frame>
    <description>The time interval from randomization to death caused by any reason</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1120</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Segmentectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive segmentectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive lobectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Segmentectomy</intervention_name>
    <description>Patients receive segmentectomy</description>
    <arm_group_label>Segmentectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lobectomy</intervention_name>
    <description>Patients receive lobectomy</description>
    <arm_group_label>Lobectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient aged 18-75 years old;&#xD;
&#xD;
          2. 6 mm ≤ tumor size ≤ 20 mm;&#xD;
&#xD;
          3. 0.25 ≤ C/T ≤ 0.75;&#xD;
&#xD;
          4. Center of tumor located in the middle third of the lung field;&#xD;
&#xD;
          5. ECOG score of 0,1 or 2;&#xD;
&#xD;
          6. Lung function (FEV1 ≥ 1 L and ≥ 70%);&#xD;
&#xD;
          7. Both lung segmentectomy and lobectomy could achieve R0 resection;&#xD;
&#xD;
          8. No serious cardiopulmonary complications, and could withstand both lung segmentectomy&#xD;
             and lobectomy;&#xD;
&#xD;
          9. No hilus pulmonis and mediastinal lymph node metastasis and no distant metastasis;&#xD;
&#xD;
         10. Written informed consent.&#xD;
&#xD;
         11. Single tumor nodule or the concomitant nodule &lt; microinvasive tumor;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. the tumor is located in right middle lobe;&#xD;
&#xD;
          2. a history of other malignancies in the last 5 years (exclusion of early-staged thyroid&#xD;
             cancer and cervical cancer in situ);&#xD;
&#xD;
          3. have received preoperative anti-tumor therapy, including prior chemotherapy, radiation&#xD;
             therapy, target therapy and so on;&#xD;
&#xD;
          4. serious mental illness;&#xD;
&#xD;
          5. Pregnant and lactating women;&#xD;
&#xD;
          6. congestive heart failure, myocardial infarction, severe stenosis of coronary artery&#xD;
             within recent 6 months;&#xD;
&#xD;
          7. With the history of cerebral infarction or cerebral hemorrhage within 6 months;&#xD;
&#xD;
          8. With the history of sustained systemic corticosteroid therapy within 1 month;&#xD;
&#xD;
          9. Other unsuitable situations;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhihua Li, M.D.</last_name>
    <phone>+86-025-68303743</phone>
    <email>lizhihua_njmu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weibing Wu, M.D.</last_name>
    <phone>+86-025-68303743</phone>
    <email>wuweibing95@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhihua Li, M.D.</last_name>
      <phone>+86-02568303743</phone>
      <email>lizhihua_njmu@126.com</email>
    </contact>
    <investigator>
      <last_name>Liang Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weibing Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.</citation>
    <PMID>30442588</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, Nakamura S, Tada H, Tsuboi M. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010 Mar;40(3):271-4. doi: 10.1093/jjco/hyp156. Epub 2009 Nov 22.</citation>
    <PMID>19933688</PMID>
  </reference>
  <reference>
    <citation>Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, Nakajima R, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H; West Japan Oncology Group; Japan Clinical Oncology Group. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907. doi: 10.1016/j.jtcvs.2019.03.090. Epub 2019 Apr 9.</citation>
    <PMID>31078312</PMID>
  </reference>
  <reference>
    <citation>Wu WB, Xia Y, Pan XL, Wang J, He ZC, Xu J, Wen W, Xu XF, Zhu Q, Chen L. Three-dimensional navigation-guided thoracoscopic combined subsegmentectomy for intersegmental pulmonary nodules. Thorac Cancer. 2019 Jan;10(1):41-46. doi: 10.1111/1759-7714.12897. Epub 2018 Nov 3.</citation>
    <PMID>30390378</PMID>
  </reference>
  <reference>
    <citation>Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.</citation>
    <PMID>24551879</PMID>
  </reference>
  <reference>
    <citation>Wu W, He Z, Xu J, Wen W, Wang J, Zhu Q, Chen L. Anatomical Pulmonary Sublobar Resection Based on Subsegment. Ann Thorac Surg. 2021 Jun;111(6):e447-e450. doi: 10.1016/j.athoracsur.2020.10.083. Epub 2021 Jan 30.</citation>
    <PMID>33524360</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Segmentectomy</keyword>
  <keyword>Lobectomy</keyword>
  <keyword>the middle third of the lung field</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

